Senores Pharma Q1 FY27 Revenue Surges 36% to ₹180 Crore, PAT Up 56% to ₹31 Crore
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180.2 crore, a 36% year-on-year increase. PAT grew 56% to ₹31 crore. Regulated Markets revenue surged 42% and Emerging Markets revenue rose 30%. The company expanded its ANDA portfolio to 58 and expects sustained growth in FY27.
The substantial revenue growth, significant improvement in profitability (EBITDA and PAT), and strategic expansion of the product portfolio and manufacturing capabilities indicate a high impact on the company's financial performance and market position.
The company reported strong year-on-year growth in revenue and profitability, with significant increases in key segments like Regulated Markets and Emerging Markets. Expansion of the product portfolio and positive future outlook contribute to the positive sentiment.
Senores Pharmaceuticals Limited announced its unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2026, following approval by the Board of Directors on July 27, 2026.
The company reported strong financial and operational performance for Q1 FY27. Consolidated revenue grew by 35.9% year-on-year to ₹180.2 crore. This growth was driven by a 41.9% increase in revenue from Regulated Markets (to ₹127.8 crore) and a 29.6% increase from Emerging Markets (to ₹37.6 crore). Branded Generics revenue saw a slight decrease of 2.4% to ₹8.0 crore, while 'Others' segment revenue grew by 29.2% to ₹6.8 crore.
Profitability also saw significant improvement. EBITDA for Q1 FY27 grew by 87% year-on-year, with a margin expansion of approximately 800 basis points. Profit After Tax (PAT) increased by 56% to ₹31 crore. The company highlighted a consistent focus on manufacturing and cost efficiency contributing to sustainable margin growth.
Senores Pharmaceuticals expanded its product portfolio, nearly doubling its Regulated Markets ANDA count from 30 in June 2025 to 58 in June 2026, with 23 ANDAs already commercialized. The Emerging Markets business showed steady growth with revenue up by approximately 30% year-on-year, achieving an EBITDA margin of around 14% driven by a focus on niche products and streamlined go-to-market strategies. Importantly, the Emerging Markets business is now cash flow positive.
The company's outlook for FY27 remains positive, expecting sustained revenue growth and expanding profitability, supported by a robust product pipeline and planned commercial launches. The addition of a Baroda-based USFDA-approved manufacturing plant is expected to enhance scalability, market access, and operating leverage, with full scale-up and further expansion anticipated over the next 12-18 months.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.